Clinical Trials

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Link : https://www.clinicaltrials.gov/ct2/show/NCT05712694
Status : RECRUITING
Population : LMS
Description : ADI-PEG 20 (arginine degrading enzyme) or Placebo Plus Gemcitabine and Docetaxel
PI : A. Razak
Centers Opened : PMH
Phase : III
IIST/Pharma : Pharma